Long-Term Data for GIVLAARI® (givosiran), including Clinical Case Reviews

Description

Please join Alnylam Pharmaceuticals and Dr. Bruce Wang as he reviews long-term efficacy and safety data for RNA interference (RNAi) therapeutic GIVLAARI® (givosiran), featuring published data from the complete 36-month ENVISION Phase III trial. Dr. Wang will also share patient cases from his practice to provide clinical perspective on treatment with GIVLAARI.

Industry Supporter: Alnylam Pharmaceuticals